Stage IV Lung Cancer Clinical Trial
Official title:
Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Squamos Cell Carcinoma of the Lung
Current therapies for Stage IV or Recurrent Lung Cancer provide very limited benefit to the
patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove
beneficial in the treatment of Stage IV or Recurrent Lung Cancer.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on patients with Stage IV or Recurrent Lung Cancer.
OVERVIEW: This is a single arm, open-label study in which patients with Stage IV or Recurrent
Lung Cancer receive gradually escalating doses of intravenous Antineoplaston therapy
(Atengenal + Astugenal) until the maximum tolerated dose is reached. Treatment continues up
to12 months in the absence of disease progression or unacceptable toxicity.
OBJECTIVES:
- To determine the efficacy of Antineoplaston therapy in patients with Stage IV or
Recurrent Lung Cancer, as measured by an objective response to therapy (complete
response, partial response or stable disease).
- To determine the safety and tolerance of Antineoplaston therapy in patients with Stage
IV or Recurrent Lung Cancer.
- To determine objective response, tumor size is measured utilizing MRI scans, which are
performed every 8 weeks for the first two years, every 3 months for the third and fourth
years, every 6 months for the 5th and sixth years, and annually thereafter.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06427369 -
An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer
|
Phase 1 | |
Terminated |
NCT01228435 -
IPI-504 in NSCLC Patients With ALK Translocations
|
Phase 2 | |
Terminated |
NCT02128373 -
A Computer-Based Intervention for Distance Caregivers of Parents With Advanced Cancer
|
N/A | |
Completed |
NCT00579215 -
Lung Cancer Informational Study (LCIS)
|
N/A | |
Completed |
NCT01556191 -
Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR
|
Phase 2 | |
Terminated |
NCT00003491 -
Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03867175 -
Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer
|
Phase 3 | |
Not yet recruiting |
NCT04985357 -
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
|
||
Active, not recruiting |
NCT04267575 -
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
|
N/A | |
Not yet recruiting |
NCT06383988 -
A Web-based Program to Help Caregivers of Lung Patients Learn About Available Supportive Care Resources
|
N/A | |
Completed |
NCT02606149 -
Truthful Information on Chemotherapy and Its Impact on Chemotherapy at the End of Life
|
N/A | |
Completed |
NCT02693080 -
CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy
|
Phase 1 | |
Completed |
NCT02318771 -
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
|
Phase 1 | |
Terminated |
NCT04005144 -
Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT03112668 -
Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners
|
N/A | |
Completed |
NCT03222258 -
Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients
|
||
Completed |
NCT05025748 -
Ask Questions (ASQ):Implementation of a Communication Intervention
|
N/A | |
Terminated |
NCT05435846 -
Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation
|
Phase 1 | |
Recruiting |
NCT06110572 -
Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
|
Phase 1/Phase 2 | |
Terminated |
NCT02109016 -
A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations
|
Phase 2 |